phase I clinical study
Bristol Myers Squibb Eyeing CLL, SLL as Additional Breyanzi Indications After Positive Readout
Around 18 percent of patients in a Phase I/II trial with aggressive, treatment-refractory forms of leukemia had complete responses on the CAR T-cell therapy.
Insilico Medicine to Begin Phase I USP1 Inhibitor Trial Following FDA IND Clearance
The firm's IND application was supported by preclinical studies showing activity of ISM3091 against BRCA-mutant and homologous repair-deficient cancers.
Phio Pharmaceuticals, AgonOx Start Phase I Trial of T-Cell Immunotherapy Combination
The firms will evaluate Phio's self-delivering RNAi compound PH-762 plus AgonOx's autologous tumor-infiltrating lymphocyte therapy in a variety of cancers.
Ideaya Biosciences, Amgen Starting Phase I/II Trial of Targeted Treatment Combo in MTAP-Null Tumors
The US Food and Drug Administration cleared the firms' investigational new drug application to evaluate IDE397 plus AMG193 in an Amgen-sponsored trial.
Nexcella CAR T-Cell Therapy Amyloidosis Trial Yields Promising Safety, Efficacy Data
At ASGCT's annual meeting, researchers shared data suggesting that the autologous cell therapy could benefit patients with the rare, multiple myeloma-associated disease.